Creating an AI-Ready Foundation | Dotmatics
The ebook from Dotmatics discusses how pharmaceutical R&D is increasingly adopting AI and machine learning to analyze massive datasets, highlighting that over one-third of large pharma executives use these technologies, and it explores recent industry trends and strategies for making R&D data AI-ready to uncover hidden insights.
Creating an AI-Ready Foundation
In pharma R&D, researchers are increasingly turning to artificial intelligence (AI) and machine learning (ML) to make sense of their massive datasets. In fact, more than one-third of large-pharma executives report using AI technologies. AI/ML technology can quickly process billions of data points, acting like a powerful flashlight that illuminates hidden patterns and insights that exist in vast amounts of data—allowing researchers to uncover and understand things that were previously too dark to see.
In this ebook, we review recent trends seen with AI in the pharmaceutical industry and explore how companies can best position themselves to ensure their R&D data are AI-ready.
Related
Scripps News America Tonight
Phil Mounteney, VP of Science and Technology at Dotmatics, explains in Scripps News America Tonight how Dotmatics Luma uses AI to transform scientific research and pharmaceutical drug discovery by accelerating innovation, lowering costs, and shortening time-to-market for modern laboratories.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
Transforming Healthcare Through AI: Dotmatics Vision for a Healthier Future
Alister Campbell, VP at Dotmatics, highlighted in an NBC North Carolina feature how AI is revolutionizing healthcare by enabling more effective use of clinical data to accelerate medical discoveries and drug development—currently supporting 15 therapies in trials—while emphasizing the need for high-quality data and trustworthy AI models, with Dotmatics actively aiding over 2 million scientists worldwide to transform medicine for a healthier future.
Maximize Your Data Impact
The article discusses how R&D leaders can maximize the impact of their data by adopting AI/ML technologies, establishing robust data infrastructures, and leveraging automation and external partnerships, as highlighted by insights from Dotmatics' collaboration with LINUS and their State of Science survey revealing scientists' strategic shifts toward automation and partnerships amid scientific and economic challenges.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.